China Pharmaceutical (600056.SH): Betahistine hydrochloride tablets and other drugs will be selected for centralized drug procurement throughout the country

Zhitongcaijing · 1d ago

Zhitong Finance App News, China Pharmaceutical (600056.SH) issued an announcement. On July 31, 2026, the company's subsidiaries participated in the bid for the 12th batch of centralized national drug procurement. According to the proposed selection results announced on-site by the State Organization Drug Joint Procurement Office, the company's products betahistine hydrochloride tablets, vonoracin fumarate tablets, vitamin B6 injections, sacubatrivalsartan tablets, esaconazole sulfate tablets, edoxaban toluene sulfonate tablets, carosulfonate injections, and valaciclovir hydrochloride tablets are to be selected for this centralized procurement.

This centralized procurement is the 12th batch of centralized drug procurement organized by the state. In the procurement cycle, medical institutions will give priority to using the selected varieties from this centralized procurement and ensure that the agreed procurement volume is completed. If the company decides to win the bid for the above products, the subsequent signing of a procurement contract and implementation will help expand the sales scale of related products, increase market share, enhance the company's brand influence, and have a positive impact on the company's future business performance.